Close Menu

NEW YORK – Puma Biotechnology said on Thursday that its licensing partner Specialized Therapeutics Asia (STA) has received marketing approval for neratinib (Nerlynx) from the Drug Control Agency of Malaysia's Ministry of Health.

Puma and STA entered an exclusive licensing agreement in 2017 to commercialize neratinib in Australia, New Zealand, and Southeast Asia.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.